Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E15.55 EPS (ttm)3.85 Insider Own0.04% Shs Outstand2.83B Perf Week3.92%
Market Cap169.31B Forward P/E15.85 EPS next Y3.78 Insider Trans-33.36% Shs Float2.83B Perf Month5.28%
Income11.17B PEG3.11 EPS next Q0.80 Inst Own75.80% Short Float1.04% Perf Quarter0.11%
Sales41.40B P/S4.09 EPS this Y176.90% Inst Trans0.17% Short Ratio2.53 Perf Half Y8.19%
Book/sh16.98 P/B3.53 EPS next Y10.86% ROA11.00% Target Price64.91 Perf Year3.50%
Cash/sh5.56 P/C10.77 EPS next 5Y5.00% ROE23.20% 52W Range51.68 - 63.11 Perf YTD6.26%
Dividend1.80 P/FCF- EPS past 5Y-6.30% ROI0.50% 52W High-3.68% Beta0.32
Dividend %3.01% Quick Ratio1.50 Sales past 5Y9.00% Gross Margin64.50% 52W Low17.63% ATR1.07
Employees70000 Current Ratio1.80 Sales Q/Q-8.20% Oper. Margin40.90% RSI (14)67.10 Volatility2.53% 1.66%
OptionableYes Debt/Eq0.44 EPS Q/Q-42.10% Profit Margin27.00% Rel Volume0.70 Prev Close59.86
ShortableYes LT Debt/Eq0.38 EarningsApr 28 BMO Payout45.40% Avg Volume11.66M Price60.79
Recom2.40 SMA204.96% SMA505.41% SMA2004.69% Volume4,265,551 Change1.55%
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Feb-03-12Reiterated Barclays Capital Overweight $38 → $40
Feb-03-12Downgrade MKM Partners Buy → Neutral $42 → $40
Nov-29-11Initiated MKM Partners Buy $38
Sep-14-11Reiterated Barclays Capital Overweight $41 → $38
May-16-11Reiterated UBS Buy $40 → $42
Feb-04-11Reiterated UBS Buy $42 → $40
May-04-15 12:50PM  Murky Situation Over the Merck Name Plagues Two Drug Makers at The Wall Street Journal
08:02AM  Weak Q1 Earnings Have Some Investors Worried.......Should You Be?
May-03-15 08:23AM  A tale of two Mercks: Confusion mounts over shared brand name at Financial Times
07:00AM  The Advantages of Owning Individual Stocks at Morningstar
May-01-15 02:38PM  Top picks in health care
01:20PM  Business events scheduled for the coming week
12:29PM  Gilead Soothes Price War Worry With Q1 Results
08:46AM  Bank Of America Reviews Gilead Earnings
Apr-30-15 11:20AM  Merck deal boosts sales but not income at Bayer at bizjournals.com
11:19AM  Is a choice between Apple and Merck stock that obvious? at MarketWatch
05:31AM  Rubella Eliminated From The Americas, Thanks To MMR Vaccine at Forbes
03:11AM  Paul T. Anastas Awarded Emanuel Merck Lectureship 2015 at noodls
01:38AM  Bayer First-Quarter Profit Rises on Xarelto, Merck Acquisition at Bloomberg
Apr-29-15 05:05PM  FDA Panel Gives Thumbs-Up To Amgen's Virus-Based Melanoma Drug at Forbes
04:15PM  Merck & Co. (MRK) Earnings Analysis: By the Numbers
03:44PM  Pfizer (PFE) Earnings Analysis: By the Numbers
03:34PM  Januvia Passes, Afrezza On Deck at Forbes
03:23PM  Bristol-Myers Squibb (BMY) Earnings Analysis: By the Numbers
03:23PM  EU Needs New Drugs to Fight Antibiotic Resistance at Barrons.com
12:34PM  What's Wall Street Been Saying About Gilead Lately?
10:52AM  April US Consumer Confidence Dips to 95.2 on Rising Fuel Costs
07:00AM  This Pharma Firm Passes the Test at Morningstar
06:00AM  Investors on Fed statement, first-quarter GDP watch at CNBC
12:21AM  Pfizer, Merck and Bristol-Myers Squibb Report Solid Results at The Wall Street Journal
12:20AM  Mercks Shrinking Revenue Doesnt Fit Its Stock at The Wall Street Journal
12:19AM  HCL celebrates 10 years of successful engagement with Merck at noodls
Apr-28-15 07:01PM  Asian stocks seen cautious on mixed US lead at CNBC +5.04%
07:00PM  New meds help drugmakers AAP
06:56PM  Investors on Fed watch as statement, GDP come out at CNBC
06:50PM  Merck Jumps, United Therapeutics Drops On Q1 Earnings at Investor's Business Daily
06:49PM  Strong Merck cancer drug sales upstage rival Bristol-Myers
06:00PM  Stocks End Higher in Choppy Trading; Fed, Earnings Eyed
06:00PM  Cramer: Twitter remains a gold mine
06:00PM  Cramer: Here's why Twitter tanked
05:54PM  Stocks end mostly higher as company earnings reports pour in
04:55PM  Merck Has the Rx for an Even Higher Stock Price at Barrons.com
04:47PM  New meds help drugmakers weather strong dollar, other issues
04:44PM  Major Drug Companies Report Solid Results at The Wall Street Journal
04:33PM  US STOCKS-Dow, S&P 500 end up with Merck, IBM; Nasdaq slips with Apple
04:16PM  Stocks Recover Off Lows, End Mixed; Twitter Crashes at Investor's Business Daily
04:05PM  Merck's Revenue Doesn't Fit Its Stock at The Wall Street Journal
04:01PM  The 4 Stocks That Boosted the Dow on Tuesday at 24/7 Wall St.
03:20PM  Stocks mostly higher as company earnings reports pour in
03:03PM  US STOCKS-Wall St edges up with Merck, IBM; Nasdaq slips with Apple
02:47PM  Stocks Recover After Volatile Start; Merck Props Up Dow at Investor's Business Daily
02:27PM  Stocks pare gains as Street eyes Fed meeting at CNBC
01:43PM  Pfizer, despite dollar and generics fight, still impresses
01:38PM  UPS gains on earnings beat; Apple comes off highs at MarketWatch
01:04PM  Merck Gains Edge on Rivals With Results About its Diabetes Drug at The Wall Street Journal
01:03PM  Merck Measles Vaccine Sales Surged as California Outbreak Grew at Bloomberg
12:47PM  Merck Up On Q1, Januvia Report; Bristol, Pfizer Mixed at Investor's Business Daily
12:29PM  Investors sour on Coach turnround efforts at Financial Times
12:27PM  Merck hurdles Wall Street forecasts
12:26PM  US STOCKS-Wall St reverses course to trade higher
12:04PM  Stocks Recover From Iran News, Weak Consumer Confidence at Investor's Business Daily
12:00PM  Stocks Higher in Choppy Trading; Fed, Earnings Eyed
11:30AM  Merck (MRK) Beats on Q1 Earnings & Revenues, Ups View - Analyst Blog
11:21AM  How Big Can Merck's Keytruda Be In Lung Cancer? at Forbes
11:20AM  Stocks fluctuate as company earnings reports pour in
11:08AM  Merck (MRK) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
10:42AM  Apples IPhones Drive Second-Quarter Sales, Profit Surge at Bloomberg
10:38AM  Merck Raises 2015 Forecast as First-Quarter Earnings Beat
10:30AM  Progress In Cancer Drug Lifts Merck Earnings, Sending Stock Higher at Forbes
10:23AM  Stocks move lower as US company earnings reports pour in
10:13AM  US STOCKS-Wall St fall as earnings disappoint
09:43AM  Pfizer cuts forecasts as strong dollar bites at Financial Times
09:41AM  How Lead Product Dependency Shapes Corporate Strategy In Pharma at Forbes
09:38AM  Merck (MRK) Stock Is Up on Earnings Beat at TheStreet
09:28AM  Dr Hugues Dolgos, Merck Serono, presenting at QSP meeting today at noodls
09:25AM  Merck says FDA again declines to approve Bridion, needs more data Reuters
09:21AM  U.S. stocks: Futures trim losses after housing data at MarketWatch
09:05AM  Heres how much more Apple earns than everyone else at MarketWatch
09:04AM  Dollar hits Pfizer; Merck 'blew away' estimates at CNBC
09:02AM  Cancers Six-Figure Potential Blockbusters Lift Drugmaker Sales at Bloomberg
09:02AM  Stock Futures Mixed, Nasdaq Up; Apple, Vasco, Merck Rising at Investor's Business Daily
08:37AM  Merck (MRK) Tops on Q1 Earnings & Revenues, Shares Up - Tale of the Tape
08:19AM  Merck tops Street 1Q forecasts
08:15AM  Despite Currencies, Merck Delivers on Earnings at 24/7 Wall St.
08:09AM  Innovation driving big pharma: Pro
08:05AM  Merck 'blew away the quarter': Pro
08:01AM  Early movers: BP, F, AAPL, BMY, COH, PFE & more at CNBC
08:00AM  Merck & Co Inc Earnings Call scheduled for 8:00 am ET today
07:51AM  Merck Sales of New Cancer Immunotherapy Top Street Estimates at TheStreet
07:48AM  Morning Movers: Coach, Whirlpool, Ford Sink on Earnings; Merck Jumps on Drug Trial Success at Barrons.com
07:33AM  Merck Raises Earnings Outlook at The Wall Street Journal
07:28AM  Big Pharmas M&A Opportunity at The Wall Street Journal
07:27AM  Merck shares up 4.5% as company beats profit, sales estimates and raises outlook at MarketWatch
07:17AM  Merck beats Q1 forecasts, helped by Januvia, animal health brands
07:07AM  Q1 2015 Merck & Co Inc Earnings Release - Before Market Open
07:06AM  MERCK & CO., INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
07:00AM  Merck Announces First-Quarter 2015 Financial Results Business Wire
06:38AM  GSK shingles vaccine shows benefits across all age groups
Apr-27-15 08:00PM  After Hours: Merck Perks; Pot Biotech Is A Downer at Investor's Business Daily
06:58PM  Cardiovascular Outcomes With Merck's Januvia: No Better Or Worse Than Conventional Care at Forbes
06:48PM  Merck diabetes drug Januvia meets heart safety target Reuters
06:30PM  Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases Business Wire
06:05PM  Merck Gains as Januvia Diabetes Drug Doesnt Add to Heart Risk at Bloomberg
05:30PM  Big pharma, big earnings?
05:29PM  Merck's diabetes drug Januvia succeeds in heart safety trial Reuters
05:00PM  Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint Business Wire
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, including antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holston Michael JEVP, LegalApr 29Option Exercise44.39135,6246,020,460135,624Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Option Exercise38.51156,9026,042,441301,697Apr 29 06:01 PM
Holston Michael JEVP, LegalApr 29Sale59.8495,6245,722,54240,000Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Sale59.82156,9029,386,646144,795Apr 29 06:01 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise33.835,000169,15011,400Apr 13 05:24 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Option Exercise31.847,082225,491358,564Feb 18 04:51 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Sale58.675,164302,959353,400Feb 18 04:51 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Option Exercise40.44135,8645,494,524242,094Feb 11 02:19 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Sale58.56135,8647,956,372106,230Feb 11 02:19 PM
WENDELL PETER CDirectorFeb 09Option Exercise33.835,000169,1506,000Feb 09 03:24 PM
WENDELL PETER CDirectorFeb 09Sale58.765,000293,7971,000Feb 09 03:24 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Option Exercise41.1874,2003,055,57874,200Jan 15 03:55 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Sale62.4874,2004,636,2240Jan 15 03:55 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Option Exercise34.2012,874440,240360,322Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Sale62.478,840552,267351,482Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEODec 10Option Exercise34.2012,874440,240357,294Dec 10 05:59 PM
FRAZIER KENNETH CChairman, President & CEODec 10Sale60.009,846590,760347,448Dec 10 05:59 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Option Exercise51.0250,0002,551,000178,467Dec 08 06:55 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Sale62.0050,0003,100,000128,467Dec 08 06:55 PM
LAZARUS ROCHELLE BDirectorNov 26Option Exercise34.1410,000341,35014,595Nov 26 12:40 PM
LAZARUS ROCHELLE BDirectorNov 26Sale59.6310,000596,3004,595Nov 26 12:40 PM
WEEKS WENDELL PDirectorNov 24Option Exercise33.835,000169,1505,100Nov 25 07:08 PM
WEEKS WENDELL PDirectorNov 24Sale59.135,000295,663100Nov 25 07:08 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise34.2012,875440,272354,420Nov 10 04:36 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale57.9810,000579,784344,420Nov 10 04:36 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthNov 02Option Exercise0.004,38704,387Nov 03 04:46 PM
FRAZIER KENNETH CChairman, President & CEOOct 10Option Exercise34.2012,875440,272351,440Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOOct 10Sale59.739,895591,033341,545Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOSep 10Option Exercise34.2012,875440,272348,379Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOSep 10Sale60.489,814593,592338,565Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOAug 11Option Exercise34.2012,875440,272345,562Aug 12 09:01 AM
FRAZIER KENNETH CChairman, President & CEOAug 11Sale57.0010,058573,306335,504Aug 12 09:01 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Option Exercise45.3823,4001,061,82042,844Aug 05 09:56 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Sale56.6428,6691,623,72014,175Aug 05 09:56 AM
REPRESAS CARLOS EDirectorAug 01Option Exercise35.195,000175,9505,500Aug 05 10:16 AM
FRAZIER KENNETH CChairman, President & CEOJul 10Option Exercise34.2012,876440,307351,474Jul 10 03:47 PM
FRAZIER KENNETH CChairman, President & CEOJul 10Sale58.039,987579,545341,487Jul 10 03:47 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Option Exercise30.01180,0475,403,278273,611Jul 08 02:16 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Sale59.16180,04710,650,93293,564Jul 08 02:16 PM
Deese Willie AExe V-P & Pres. MMDJun 27Option Exercise27.8572,2902,013,164178,512Jun 30 04:23 PM
Deese Willie AExe V-P & Pres. MMDJun 27Sale58.2672,2904,211,254106,222Jun 30 04:23 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 14Sale55.9110,527588,5840May 14 02:48 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Option Exercise34.2012,876440,307345,927May 13 03:56 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Sale55.0010,220562,100335,707May 13 03:56 PM